Get startedLog in
    Picture of Madrigal Pharmaceuticals logo

    MDGL — Madrigal Pharmaceuticals News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapMomentum Trap
    All News

    Brief: Madrigal Announces Two-Year Data From The Compensated Mash Cirrhosis Arm Of The Maestro-Nafld-1 Trial

    Picture of Madrigal Pharmaceuticals logoMadrigal Pharmaceuticals
    26/02/2025 12:52
    Feb 26 (Reuters) - Madrigal Pharmaceuticals Inc MDGL.O:

MADRIGAL ANNOUNCES NEW TWO-YEAR DATA FROM THE COMPENSATED MASH CIRRHOSIS ARM OF THE MAESTRO-NAFLD-1 TRIAL DEMONSTRATING POTENTIAL BENEFIT OF REZDIFFRA™ (RESMETIROM) IN PATIENTS WITH COMPENSATED MASH CIRRHOSIS

MADRIGAL PHARMACEUTICALS INC - REPORTS POSITIVE TWO-YEAR RESULTS FROM PHASE 3 TRIAL

MADRIGAL PHARMACEUTICALS INC - SAFETY PROFILE OF REZDIFFRA CONSISTENT WITH OTHER TRIALS

Source text: ID:nGNXbShBP0

Further company coverage: MDGL.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Madrigal Pharmaceuticals

    See all news